Latent Labs Launches Latent-X, a Frontier Generative AI Model for Protein Binder Design Accessible via No-Code Platform for Push-Button Protein Design

Latent Labs, a company founded by Simon Kohl(Co-developer of Deepmind's AlphaFold2 and co-lead of Deepmind's protein design team), with an excellent team including Alex Bridgland(Founding Member Technical Staff), Annette Obika-Mbatha(Head of Operations), Dave Yuan(Head of Platform), Sandy Nelson(Strategy and Talent), Rebecca Bartke-Croughan(Platform Scientist), Daniella Pretorius(Computational Protein Design Scientist), Mária Vlachynská, Krishan Bhatt(People and Talent), and members of Technical Staff including Jonathan Crabbé, Henry Kenlay, Agrin Hilmkil, Tomas Matteson, Simon Mathis, and Sebastian Schmon, launched Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions. Just five months ago, Latent Labs announced a $50M funding round co-led by Radical Ventures and Sofinnova Partners, with backing from top tech leaders including Google’s Jeff Dean, Anthropic’s Dario Amodei, and Eleven Labs’ Mati Staniszewski.

Latent's new model is now available for early access on its no-code AI protein design platform. Users can upload protein targets and generate cyclic peptides and mini-binders directly in the browser, with tools to explore, score, and select top-ranked designs for lab testing. The platform offers a free tier for both commercial and non-commercial users, with sign-up open at platform.latentlabs.com.

Latent Labs uses generative AI to transform drug discovery, replacing slow, costly screening with automated design. Its platform, Latent-X, can generate high-confidence binders with just 30 candidates per target—cutting time, cost, and failure rates.

Latent-X is a next-gen AI model for de novo binder design, delivering up to 100% hit rates and picomolar affinities across 7 targets in lab tests. It outperformed prior generative tools and enables rapid design of macrocycles and mini-binders—both promising drug modalities. Accessible via Latent Labs’ intuitive platform, Latent-X designs binders for novel proteins in seconds, generating accurate, all-atom structures that generalize beyond nature. The company is now seeking partners to expand into nanobody, antibody, and other therapeutic applications.